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Background: Manuscript abstracts represent a critical source of information for oncology practitioners.
Practitioners may utilize the information contained in abstracts as a basis for treatment decisions particularly
when full-text articles are not accessible. In 2007, the Consolidated Standards of Reporting Trials (CONSORT)
extension statement for abstracts provided a minimum list of elements that should be included in abstracts.
In this study we evaluate the degree of adherence to these recommendations and accessibility of full text
publications in oncology publications.
Methods: A systematic review of abstracts of randomized, controlled, phase III trials in metastatic solid malignancies
published between January 2009 and December 2011 in PubMed, Medline, and Embase was completed. Abstracts
were assigned a completeness score of 0–18 based on the number of CONSORT-recommended elements. Accessibility
through open access was recorded.
Results: 174 abstracts with data for 95,956 patients were reviewed. The median completeness score was 9 (range,
3–17). Open access to full text articles was available for 80 % of abstracts. The remaining 20 % (35 out of 174)
had a median cost of 38 USD (range: $22–49.95). The least frequently reported elements were: trial design
description (20 %), participant allocation method (13 %), blinding (24 %), trial enrollment status (22 %),
registration and name of trial (26 %) and funding source (18 %). The most frequently reported elements were
eligibility criteria (98 %), study interventions (100 %), and primary endpoint (87 %).
Conclusion: There is poor adherence to the CONSORT recommendations for abstract reporting in publications of
randomized cancer clinical trials which could negatively impact clinical decision-making. Full-text articles are
frequently available through open access.
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Clinicians utilize peer-reviewed publications to guide the
management of patients with cancer. Clinical trial publica-
tions provide clinicians with an understanding of the spe-
cific patient population that was studied, the details of the
experimental intervention, and the potential harms and
benefits. Given the importance placed on clinical trials,
guidelines, such as those generated by the Consolidated
Standards of Reporting Trials (CONSORT) group, have* Correspondence: ssivendran2@lghealth.org
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An abstract is a concise summary of a clinical trial
that is frequently utilized by clinicians to decide
whether or not a study is of sufficient interest to read
the full text. For many clinicians, such as those practicing
in community-based settings or low and middle income
countries, financial and/or information technology
barriers limit access to full-text publications and the
publically available abstract may be the only source of
clinical trial information. However, several analyses
have demonstrated inconsistencies in the data presentedcle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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could potentially impact interpretation of the study results
[3–9]. Similar inconsistencies have been reported
when comparing abstracts presented at scientific
meetings with the final study results published in
peer-reviewed journals [10–14]. To address these dis-
crepancies, the CONSORT group published an exten-
sion statement in 2008 concerning the quality of
reporting in journal and conference abstracts. A 17
item checklist with explanations and examples was
generated to establish uniform standards of abstract
reporting [15]. In this analysis we assess the degree to




Citations were reviewed from Medline, PubMed, and
Embase published between 1 January 2009 and 31
December 2011 to identify eligible publications for ana-
lysis. ‘Metastatic” or ‘advanced” were the key words in-
cluded in the search and were further refined using the
following filters: ‘publication dates = 1/1/2009-12/31/
2011’; ‘subjects = cancer’; ‘article type = clinical trial,
phase III’; ‘language = English’; and ‘species = human.’
Publications that included patients with metastatic solid
tumors receiving a pharmacologic intervention in a
phase III clinical trial, as indicated by study authors,
were included in the analysis. All other studies, includ-
ing phase I and II studies, observational studies, letters,
case reports, editorials, and studies exploring a device or
behavioral intervention, were excluded. In the setting
where multiple publications were found from the same
trial, only the initial publication was used for the ana-
lysis. If the initial publication was published prior to
2009, neither that publication nor subsequent related
publications were included in the analysis.
Data extraction
The CONSORT extension for abstract reporting outlines
17 general recommendations (Table 1) [15]. Additional
recommendations are found in an accompanying paper
entitled ‘CONSORT for reporting randomized controlled
trials in journal and conference abstracts: explanation and
elaboration.’ A multidisciplinary panel of five providers
reviewed these recommendations and assembled a con-
sensus list of 18 key reporting elements that were used in
data collection and outlined in Table 1. The reporting
element ‘Eligibility criteria for participants and the settings
where the data were collected’ was divided into two separ-
ate reporting elements - ‘Eligibility criteria for participants’
and ‘The settings where the data was collected.’Allocation
concealment was evaluated based on specific criteria pro-
vided by the CONSORT committee's explanations andelaborations [15]. One CONSORT recommendation not
included was ‘contact details for the corresponding author’
as this is specific to conference abstracts and no confer-
ence abstracts were reviewed in our analysis.
Eligible publications were evaluated for each of the 18
reporting elements in the abstract only. Additional data
were extracted from either the abstract or full-text manu-
script including the sample size, intervention type, use of
placebo control, publication year, funding source, journal
name and impact factor, and whether the primary study
endpoint was met and specifically commented on in the
discussion portion of the abstract. We also investigated
whether the manuscript was available in full-text form
though open access. If the full text was not available
through open access, we recorded the cost (in US dollars)
to access the full-text manuscript. Finally, we recorded
whether the article was published in a journal that en-
dorses the CONSORT statement.
The intervention types were classified as targeted
therapy, chemotherapy, immunotherapy, or hormonal
therapy. The primary endpoint was obtained from
either the abstract or full manuscript. The results
section was reviewed to determine if the primary end-
point was met. We compared regulatory approval
dates derived from the Drugs@FDA Website with the
manuscript publication date to assess whether the
intervention was approved for another indication. Data
extraction was done by two independent reviewers (SS
and KN) and discrepancies resolved by a third reviewer
(AA). Inter-rater agreement x kappa values ranged
from 0.66 to 1.00 with a mean ± standard deviation of
0.88 ± 0.10.
Statistical analysis
The primary objective of this systematic review was to
describe the quality of abstract reporting in phase III
randomized controlled trials of systemic therapy for
metastatic solid tumors in the context of the CONSORT
abstract extension statement. Quality of abstract
reporting was defined by the ‘completeness score’, cal-
culated as the total number of CONSORT elements
(Table 1) reported in each abstract. Each abstract re-
ceived a score of 0–18. The secondary objective was to
determine which clinical trial characteristics were asso-
ciated with the ‘completeness score.’ We constructed
linear models to assess the unadjusted association be-
tween the completeness score and covariates in the ab-
stracts. This facilitated the assessment of categorical
and continuous covariates in the same model structure.
An exploratory objective was to describe the accessibility
of full-text manuscripts through open access. All analyses
were performed using Stata version 13.1 (College Station,
TX, USA) using two-sided p values and p <0.05 con-
sidered as significant.
Table 1 Elements of abstract reporting




Title 1. Identification of the study as randomized Identification of the study as randomized 1
Authors 2. Contact details for the corresponding
author
Not included in the current analysisa
Trial design 3. Description of the trial design (e.g., parallel,
cluster, non-inferiority)
Abstract specifies whether specific description of the trial
design was included (e.g., parallel, cluster, non-inferiority)
2
Methods 4. Eligibility criteria for participants and the
settings where the data were collected
Abstract specifies the eligibility criteria for participants
relating to demographics, clinical diagnosis, and co morbid
conditions.
3
Abstract specifies the setting in which the trial took
place (for example primary, secondary, tertiary centers)
4
5. Interventions intended for each group Abstract specifies medication intervention intended
for each study group
5
6. Specific objective or hypothesis Abstract specifies the objective or hypothesis of the study 6
7. Clearly defined primary outcome for
this report
Abstract clearly states the primary outcome or endpoint in
the study
7
Abstract describes over what period of time the primary
outcome or endpoint was assessed
8
8. How participants were allocated to
interventions
Abstract describes the method by which participants were
assigned to interventions to ensure adequate concealment
(e.g. use of computer or random number table)
9
9. Whether or not participants, care givers,
and those assessing the outcomes were
blinded to group assignment
Abstract specifies whether participants, care givers, and
those assessing the outcomes were masked or blinded to
the group allocation
10
Results 10. Number of participants randomized to
each group
Abstract reports absolute numbers of patients randomized to
each group
11
11. Trial status Abstract reports the status of the trial and whether it is
ongoing, closed to recruitment or closed to follow-up
12
12. Number of participants analyzed in each
group
Abstract reports either absolute numbers analyzed in each
group or indicates this is an intention to treat analysis
13
13. For the primary outcome, a result for each
group and the estimated effect size and
its precision
Abstract reports trial results as a summary of the outcome
for each group and the contrast between the groups
(examples include relative risk, odds ratio, hazard ratio,
confidence intervals)
14
Harms 14. Important adverse events or side effects Abstract explicitly describe any important or unexpected
adverse events
15
Conclusions 15. General interpretation of results Abstract states conclusions of the trial consistent with
reported results.
16
16. Registration number and name of trial
register
Abstract reports registration number and name
of trial register
17
17. Source of funding Abstract lists funding source for study 18
aNot included in the current analysis as the multidisciplinary panel that reviewed the CONSORT abstract extension statement concluded that this element is
specific to conference abstracts
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Literature search
Of the 589 potentially relevant publications identified in
our search, 174 publications met the eligibility criteria
for inclusion in the analysis. The reasons for study inclusion
and exclusion are detailed in Fig. 1.
The characteristics of the publications included in
the analysis are detailed in Table 2. A total of 95,956
patients were involved in the trials included in this re-
view with THE median sample size being 421 (range19–4,312). Breast cancer was the most common can-
cer subtype explored (21 %) and chemotherapy was
the most common intervention (48 %). The majority
of studies were supported by industry.
Abstract reporting
The proportion of abstracts reporting each of the 18
reporting elements is shown in Table 3. The majority of
the abstracts did not provide a specific description of the
trial design (20 %) or the setting in which the trial took
Fig. 1 Flowchart of screening of publications included in the analysis
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assigned to interventions to ensure concealment was
only reported in 13 % of abstracts and masking or blinding
of the group allocation was only reported in 24 % of ab-
stracts. Most abstracts did not report the time period over
which the primary outcome was assessed (17 %) or how
many patients were analyzed in each group (26 %).
Some reporting elements were applied more consist-
ently across abstracts. All of the abstracts analyzed re-
ported the intervention intended for each study group
(100 %). The objective or hypothesis was reported in 95
% of abstracts and the primary outcome was reported
in 87 % of abstracts. Summary statistics for the out-
come for each group (87 %) and conclusions based on
the results reported in the abstract (95 %) were re-
ported consistently. Important or unexpected adverse
events were reported in 74 % of abstracts.
Abstract reporting completeness scores
The mean ± standard deviation completeness score was
9.2 ± 2.7 (range 3–17; Fig. 2). Among 174 abstracts ana-
lyzed, 144 (83 %) were published in journals that en-
dorse the CONSORT recommendations. There was no
significant difference in completeness scores between ab-
stracts published in journals that do (9.3 ± 2.8), and do
not (8.7 ± 2.1) endorse the CONSORT recommenda-
tions (p = 0.241). There were also no significant differ-
ences in the mean completeness scores for placebo-
controlled trials, treatment type or funding source (see
Table 4). We did find differences (p = 0.014) in the mean
completeness score for studies that had interventionsapproved for another indication (8.9 ± 2.6) having lower
completeness scores than for studies with interventions
not approved for another indication (10.1 ± 2.9). If the
trial met the efficacy endpoint, the mean completeness
score was higher (9.8 ± 3.0) than if the trial did not meet
the efficacy endpoint (8.8 ± 2.4) (p = 0.018). We also
found a linear trend with increasing completeness scores
based on the year of publication across 2009, 2010 and
2011 (p = 0.039).
Accessibility of full-text manuscripts through open access
Of the 174 abstracts reviewed for our analysis, the ac-
companying full text of the manuscript was available
through open access in 80 % (139/174). There was no
significant difference in the mean completeness scores
for publications that were available free of charge versus
those that required purchase (9.4 ± 2.8 versus 8.7 ± 2.3
respectively; p = 0.210). The median cost to purchase
an article not available through open access was 38 US
dollars (range: $22–$49.95).
Conclusion
An abstract is a snapshot of the overall design and re-
sults of a clinical trial and in many circumstances may
be the only portion of a manuscript read by a clinician
due to time constraints and barriers to accessing full-
text publications. Therefore, sufficiently detailed and
transparent reporting of oncology clinical trial abstracts
is critical. Several guidelines have been developed, in-
cluding those from the CONSORT group, in an effort to
standardize the quality of abstract reporting [1, 2, 4, 15].
Table 2 Characteristics of studies included in analysis (n = 174)
Characteristic Value
Median sample size (range) 421 (19–4,312)
Placebo-controlled 45 (26 %)
Intervention type
Chemotherapy 83 (48 %)
Hormonal therapy 7 (4 %)
Targeted therapy 60 (34 %)
Immunotherapy 11 (6 %)
Chemotherapy + targeted therapy 7 (4 %)
Chemotherapy + immunotherapy 6 (3 %)
Trial met primary endpoint 75 (43 %)
Funding source
Industry 112 (64 %)
Government 16 (9 %)
Industry and Government 14 (8 %)
Other 9 (5 %)
Funding source not reported 22 (13 %)
No funding 1 (<1 %)
Experimental drug approved for other indication 132 (76 %)
Year of publication
2009 49 (28 %)
2010 58 (33 %)
2011 67 (39 %)
Cancer type
Breast 37 (21 %)
Colorectal 19 (11 %)
Gastric or gastroesophageal 8 (5 %)
Head and neck 5 (3 %)
Lung 37 (21 %)
Melanoma 9 (5 %)
Ovarian 12 (7 %)
Pancreas 11 (6 %)
Prostate 9 (5 %)
Renal 8 (5 %)
Other 19 (11 %)
Journal
Annals of Oncology 16 (9 %)
Breast Cancer Research and Treatment 6 (3 %)
British Journal of Cancer 3 (2 %)
Cancer 5 (3 %)
European Journal of Cancer 10 (6 %)
Journal of Clinical Oncology 60 (34 %)
Lancet 11 (6 %)
Lancet Oncology 12 (7 %)
Table 2 Characteristics of studies included in analysis (n = 174)
(Continued)
New England Journal of Medicine 14 (8 %)
Other 37 (21 %)
Impact factor of journals, median (range) 18 (1–53)
Results are presented as number (%) unless stated otherwise
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ment for reporting randomized controlled trials in journal
and conference abstracts, there is significant heterogeneity
in reporting of individual elements as demonstrated by
our analysis and that of others [16–23].
Variability in reporting randomized controlled trials in
journal abstracts may be secondary to several factors.
Authors may be unaware of the CONSORT extension
recommendations and journals may not require or en-
force compliance to these guidelines. The CONSORT
extension guidelines are not oncology specific and em-
phasis on certain reporting elements may be different
for various disciplines. Limitations on word count for
abstracts may also impact the ability of authors to com-
ply with the CONSORT recommendations.
Notably, our unadjusted analyses demonstrated that
most analyzed variables, including journal endorse-
ment of CONSORT recommendations, placebo con-
trolled trials, treatment type, or funding source, were
not associated with completeness of abstract reporting.
This suggests that suboptimal reporting is not limited
to subsets of journals but rather a generalized issue.
Interestingly, we reported that completeness scores
have been linearly increasing over time as publications
from 2011 had higher completeness scores. Our inclu-
sion of publications spanning only a 3 year time inter-
val (2009–2011), however, limits the interpretation of
this finding.
There are several prior analyses addressing the quality
of abstract reporting in randomized clinical trials but the
majority of these have not evaluated oncology trials.
However, during the preparation of this manuscript,
Ghimire et al. published an analysis of oncology ran-
domized controlled trials over a three-year period both
prior to and after adoption of the CONSORT extension
statement for abstract reporting. Substantial heterogen-
eity and selectivity in the quality of abstract reporting
was demonstrated with only half of the CONSORT rec-
ommendations consistently being reported after the
adoption of the CONSORT extension statement [24].
Our analysis extends these findings in several ways. We
investigated the potential association between several
study characteristics and abstract reporting completeness.
For example, we demonstrated that journal endorsement
of the CONSORT statement was not associated with ab-
stract reporting completely, nor was public availability of
Table 3 Proportion of articles addressing each of the 18 abstract reporting elements (n = 174)
Reporting elements Number (%)
1. Identification of the study as randomized 100 (57 %)
2. Abstract specifies whether specific description of the trial design was included (e.g., parallel, cluster, non-inferiority) 34 (20 %)
3. Abstract specifies the eligibility criteria for participants relating to demographics, clinical diagnosis, and comorbid conditions. 171 (98 %)
4. Abstract specifies the setting in which the trial took place (e.e., primary, secondary, tertiary centers) 24 (14 %)
5. Abstract specifies medication intervention intended for each study group 174 (100 %)
6. Abstract specifies the objective or hypothesis of the study 166 (95 %)
7. Abstract clearly states the primary outcome or endpoint in the study 151 (87 %)
8. Abstract describes over what period of time the primary outcome or endpoint was assessed 29 (17 %)
9. Abstract describes the method by which participants were assigned to interventions to ensure adequate concealment
(e.g., use of computer or random number table)
22 (13 %)
10. Abstract specifies whether participants, care givers, and those assessing the outcomes were masked or blinded to the group
allocation
42 (24 %)
11. Abstract reports absolute numbers of patients randomized to each group 80 (46 %)
12. Abstract reports the status of the trial and whether it is ongoing, closed to recruitment or closed to follow up 39 (22 %)
13. Abstract reports either absolute numbers analyzed in each group or indicates this is an intention-to-treat analysis 45 (26 %)
14. Abstract reports trial results as a summary of the outcome for each group and the contrast between the groups (examples
include relative risk, odds ratio, hazard ratio, confidence intervals)
152 (87 %)
15. Abstract explicitly describes any important or unexpected adverse events 129 (74 %)
16. Abstract states conclusions of the trial consistent with reported results. 168 (97 %)
17. Abstract reports registration number and name of trial register 46 (26 %)
18. Abstract lists funding source for study 31 (18 %)
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factors, including authors’ lack of awareness of the guide-
lines or journals lack of enforcement of guidelines, may
potentially be contributing to the poor quality of abstract
reporting. Another study done prior to adoption of theFig. 2 Distribution of abstract reporting completeness scores (n = 174). Th
reporting elements addressed in each abstractCONSORT extension statement utilized a checklist de-
rived from the original CONSORT statement and applied
to American Society of Clinical Oncology Annual Meeting
abstracts and also demonstrated the generally poor quality
of abstract reporting.e completeness score was derived by adding each of the 18 abstract
Table 4 Publication characteristics associated with abstract
reporting completeness score
Publication characteristics Number Completeness





No 30 8.7 ± 2.1
Yes 144 9.3 ± 2.9
Placebo controlled 0.532
No 129 9.3 ± 2.7
Yes 44 9.0 ± 2.6
Treatment type 0.789
Chemotherapy 83 9.1 ± 2.8
Targeted 60 9.4 ± 2.7
Othera 31 9.2 ± 2.5
Funding source 0.729
Industry 112 9.3 ± 2.7




No 43 10.1 ± 2.9
Yes 131 8.9 ± 2.6
Year of publication 0.039
2009 49 8.6 ± 2.7
2010 58 9.0 ± 2.4
2011 67 9.9 ± 2.8
Trial met efficacy endpoint 0.018
No 99 8.8 ± 2.4
Yes 75 9.8 ± 3.0
Open access (available free) 0.210
No 35 8.7 ± 2.3
Yes 139 9.4 ± 2.8
aOther treatment type includes chemotherapy and immunotherapy,
chemotherapy and targeted, hormonal, and immunotherapy
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gent application of the CONSORT guidelines during the
peer review process in improving the quality of abstracts.
Hopewell et al. conducted an interrupted time series
analysis of the quality of abstracts describing medical
randomized controlled trials both before and after the
implementation of the CONSORT extension statement
for abstracts in five leading medical journals. Journals
were divided into three categories - those that did not
endorse the CONSORT guidelines, those that endorsed
the CONSORT guidelines but did not have an active
policy to enforce them, and those that endorsed the
CONSORT guidelines and had an active editorial
process to enforce them. Interestingly, there was only a
significant change in the mean number of items reportedpre and post implementation of the CONSORT exten-
sion statement in the journals that had an editorial
process to enforce the guidelines during the peer review
process [25]. This highlights the importance of not only
awareness of the guidelines by authors but the need for
implementation and enforcement of these guidelines
during the editorial review. Cobo et al. investigated the
effect of adding an additional review based on reporting
guidelines to the conventional peer review process for
all original research manuscripts submitted to one jour-
nal. The overall quality of the manuscripts was im-
proved with the addition of a second guideline-based
review. Interestingly, during the editing process, au-
thors were more likely to make manuscript revisions
based on the conventional reviews rather than the
guideline-based reviews. The authors postulated several
potential reasons for this including a lack of awareness
of these guidelines when designing a research study,
making it more difficult to adhere to reporting certain
elements in the publication process [26].
Accurate and transparent reporting of clinical trial
information in abstracts may be particularly important
in situations in which there is no access to full-text ar-
ticles. Community oncologists, who provide 85 % of
the cancer care in the USA, as estimated by the Na-
tional Cancer Institute, are less likely to have compre-
hensive journal access and may be less likely to read
multiple full-text articles when payment is required.
The cost of purchasing these articles may be prohibi-
tive to oncology physicians in the developing world
where cost and access to information technology is po-
tentially prohibitive, and who may rely only on the ab-
stract content to make clinical decisions. Fortunately,
we did find that open access to full-text articles was
available in 80 % of our dataset. It is arguably more im-
perative for conference abstracts, in which a full text
of a research study is not yet available, to stringently
follow CONSORT guidelines as this is the only reflec-
tion of the details of a study.
There are some limitations to our study. This analysis
was conducted specifically in randomized phase III
metastatic solid tumor trials and further standardization
of reporting may be necessary for other types of trials
and disease states. The analysis included only English
language studies. The importance of certain reporting
elements may not be agreed upon universally by all au-
thors or sub-specialities. Some may argue that several of
the most poorly reported elements such as the setting in
which the trial took place, reporting of allocation con-
cealment, recruitment status, registration number, and
funding source are important elements to include in the
full text but are not necessarily informative in the ab-
stract. Removal of these may raise completeness scores
as well as allow researchers more word space to address
Sivendran et al. Trials  (2015) 16:341 Page 8 of 8other key trial details in the abstract. Future studies are
needed to address this.
Importantly, CONSORT guidelines and extension
statements represent a minimum standard in report-
ing. Adoption and expansion of these guidelines by
the oncology community, and implementation and en-
forcement of these guidelines by journal editors, will
potentially lead to greater adherence and improved
quality of publications and improved clinical decision
making.
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